Regulatory Focus™ > News Articles > 6 > Recon: Dementia Discovery Fund Raises $350M to Invest in New Drugs

Recon: Dementia Discovery Fund Raises $350M to Invest in New Drugs

Posted 25 June 2018 | By Ana Mulero 

Recon: Dementia Discovery Fund Raises $350M to Invest in New Drugs

In Focus: US
  • Scripps Research, AbbVie join in large cancer therapy alliance (The San Diego Union-Tribune) (C&EN) (Fierce) (Endpoints)
  • Pfizer's breast cancer drug combo falls short of survival goal (Reuters) (Endpoints)
  • Roche’s Tecentriq scoops up a big win in small cell lung cancer, grabbing the lead in frontline cases (Endpoints) (Reuters) (PMLiVE)
  • How CRISPR Gene Editing Is Revolutionizing Medicine And The Companies Who Invest In It (Forbes)
  • Sophiris stops additional doses in topsalysin prostate cancer trial following patient death (Fierce) (Endpoints)
  • Merrimack Halts Development of Pancreatic Cancer Candidate After Phase II Failure (GEN) (Reuters) (Endpoints)
  • Enthusiasm for GSK's Shingrix has supplies falling short (BioPharma Dive) (Reuters)
  • Eli Lilly Beats Dr. Reddy's In Cancer Drug Patent Suit (Law360-$) (Economic Times)
  • Novo’s Ozempic beats Lilly’s Trulicity on weight loss (PharmaTimes) (Reuters)
  • Implantable Glucose Sensor Bests Competitors in Head-to-Head (Medscape) (MedPage Today)
  • Senators want oversight of biosimilar drug delay tactics (Axios)
  • The Common Drug That May Make Opioid Overdose Five Times As Likely (Forbes)
Sponsored Content: In-Depth IVDR/MDR Kick Starter Kit In Focus: International Pharmaceuticals & Biotechnology
  • Amazon-Berkshire-JPMorgan Health Venture Takes Aim at Middlemen (Bloomberg)
  • What you need to know about this record-setting biotech IPO burst as 5 more crash the party looking for $547M (Endpoints)
  • J&J says real-world data finds no amputation risk for Invokana (PMLiVE) (Fierce)
  • Cambridge biotech startup grabs $65M to tackle liver disease (Boston Business Journal-$) (Fierce) (Endpoints) (BioSpace)
  • Food-sourced microbiome drugs get $101M megaround for Flagship’s Kaleido (Endpoints)
  • Endocrine specialist Crinetics tees up for $86M IPO (Fierce)
  • House Passes Sweeping Opioid Treatment, Medicare Bill (Law360-$)
  • Opioid bills could net millions for companies (Politico)
  • A Drug Costs $272000 a Year. Not So Fast, Says New York State. (NYT)
  • Erytech confirms focus of eryaspase on solid tumors and ceases development in acute lymphoblastic leukemia (PBR)
  • Ohio peels back the curtain on a lucrative PBM profit center (STAT-$)
  • Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease (Press)
  • Evotec achieves second milestone in diabetes alliance with Sanofi (Press)
Pharmaceutical and Biotechnology: Study Results, Filings and Designations
  • CRISPR-Cas9 Gene Editing Reduces Repetitive Behavior In Mice With Autism-Like Syndrome (Forbes)
  • ADA: Novo Nordisk touts oral semaglutide's pivotal win as Ozempic launch revs up (Fierce)
  • GLP-1 Drug Boosts T1D Control (MedPage Today)
  • Sotagliflozin Tx Tied to HbA1c Reductions in T1D  (MedPage Today)
  • Lilly's Jardiance meets main goal of two diabetes trials (Reuters) (Press)
  • Gut Microbiome Understanding Insight Facilitated by New Platform (GEN)
  • Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache (Press)
  • First-ever Study of Lilly's Humulin R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes (Press)
  • Pluristem and Fukushima University Report Positive Data: PLX-R18 Increases Survival Rates and Mitigates Severe Intestinal Damage after Acute Radiation Exposure (Press)
  • Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS (tagraxofusp; SL-401) for the Treatment of BPDCN (Press)
  • FDA Accepts Supplemental Biologics License Application for Merck’s KEYTRUDA (pembrolizumab) as Adjuvant Therapy in Advanced Melanoma (Press)
  • Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes Care (Press)
  • New Data Show Amgen's Repatha (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes (Press)
  • Array BioPharma announces a 62% observed survival at one year from the phase 3 beacon CRC safety lead0in of the combination of encorafenib, binimetinib and cetuximab in BRAF-mutant CRC at the ESMO 20th World Congress on Gastrointestinal Cancer (Press)
  • Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes (Press)
  • Pulmatrix Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE Formulation of Itraconazole (Press)
  • Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes (Press)
  • Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies at the Inaugural AACR International Meeting Advances in Malignant Lymphoma (Press)
  • Synlogic Presents New Preclinical Data from Synthetic Biotic Immuno-Oncology Program at FOCIS 2018 (Press)
Medical Devices
  • 23andMe's test for a breast-cancer gene can reveal life-changing information, but can also lead down an expensive and complicated path (CNBC)
  • Is Robotic Prostate Surgery Better Than Traditional Surgery? (WSJ)
  • Novel Systems Could Expand 'Hybrid Closed-Loop' Field in Diabetes (Medscape)
  • FDA clears catheter-based hemodialysis vascular access systems (Fierce)
  • Roche, Care Innovations partner to build mySugr into telehealth service (Fierce)
  • FDA's second draft Pre-Cert released but real rule-making needed (Healthcare IT News)
  • Stereotaxis, J&J’s BioSense Webster extend deal for magnetic ablation catheters (MassDevice)
  • Potential Major Changes in Updated Draft Pre-Sub Guidance (FDA Law Blog)
  • Glaukos Announces FDA Approval for the iStent inject Trabecular Micro-Bypass System (Press)
  • Beckman Coulter Files a 510(k) Submission with the FDA for Its Early Sepsis Indicator (Press)
  • New Late-Breaking Data at ADA Underscore Significant Benefits of Abbott's FreeStyle Libre System for People Living with Diabetes (Press)
  • MiniMed 670G System Real-World Data Show Improved Time in Range and Reduced Lows and Highs Across All Patient Groups Including a 41 Percent Time in Range Improvement for Previous MDI Patients (Press)
  • Essential Medical Announces Positive Results From the SAFE MANTA Clinical Trial, the First Pivotal Trial for a Dedicated Large Bore Closure Device (Press)
  • Draeger Medical Systems, Inc. Jaundice Meter JM-103 and Jaundice Meter JM-105 Recalled Due to Misinterpretation of Display Messages for Out of Range Values (FDA)
US: Assorted & Government
  • Nearly 400 people used California assisted death law in 2017 (AP News)
  • The Dems Take Obamacare on the Road (Bloomberg)
  • Poll: 66% Of Voters Oppose Trump DOJ's Move To Gut Patient Protections (Forbes)
  • GOP tries to balance focus on health care costs, ACA repeal (Axios)
  • Here’s why Trump’s plan to consolidate food safety efforts won’t work (Food Safety News)
  • Why Apple should hire your grandmother (CNBC)
  • Why Atul Gawande Will Soon Be The Most Feared CEO In Healthcare (Forbes)
  • How Atul Gawande landed perhaps the most extraordinary (or impossible) job in health care (STAT)
  • Michigan governor signs controversial Medicaid work requirement bill (The Hill)
  • Reversal of fortune: Obamacare rate hikes pose headache for Republicans (Politico)
  • Antimicrobial Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments (FDA)
Upcoming Meetings & Events Europe
  • NHS Trust plans first internet addiction centre (PharmaTimes)
  • Can Cannes push the pharma ad envelope? Record number of Lions wins hint at yes (Fierce)
  • Overcoming Europe's health challenges requires bold political choices (The Parliament Magazine)
  • NHS England and UK Space Agency launch multi-million pound drive to improve patient care (NHS England)
  • European Commission Grants Marketing Authorization for Gilead’s Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection (Press)
  • Medtronic Receives CE Mark for MiniMed(TM) 670G Hybrid Closed Loop System (Press)
  • Pharma MSMEs need to adopt backward integration to offset dependence on China: Manoj Palrecha (Pharmabiz)
  • China accelerates drug review timelines for rare, life-threatening diseases (BioCentury)
  • WuXi, Harbour BioMed form development and manufacturing collaboration (PBR)
  • How are drug makers going to make money in China? An explainer (STAT-$)
  • CDSCO nod not mandatory to make unapproved drugs for export, DTAB clears proposal to empower state authorities (Pharmabiz)
  • Relief for drug manufacturers as DoP directs NPPA to revise ceiling price of tetanus toxoid vaccine injection (Pharmabiz)
  • Gujarat FDCA, Abbott conclude capacity building programme on new MD Rules and DPCO for regulators (Pharmabiz)
  • Package rates in Ayushman Bharat scheme will put patient safety at stake: IMA (Economic Times)
  • Australian watchdog appeals to high court on Pfizer's alleged abuse of market power (Reuters)
  • Medical appointment booking app HealthEngine sharing clients' personal information with lawyers (ABC News)
  • New HealthEngine scandal raises scrutiny of digital health consent practices as Health Minister orders urgent review (Healthcare IT News)
  • Rare diseases, expensive drugs - Health Canada showdown coming (The Globe and Mail)
  • B.C. considers forcing drug companies to disclose payments to doctors (The Globe and Mail)
  • Government of Canada investing $75 million in seniors' health (Health Canada)
  • Cannabis clinics may break health-care rules by charging patients to see doctor (CBC News)
  • Clostridium difficile infections have decreased 36 per cent in Canadian hospitals: study (The Globe and Mail)
  • Information Update - Health Canada reminds Canadians of the limitations of fentanyl test strips being used to check street drugs before consumption (Health Canada)
General Health & Other Interesting Articles
  • A bygone pre-existing condition shouldn’t keep my son from getting health insurance (STAT)
  • Individuality In Healthcare Is Here - Pair It With Inclusion To Achieve Better Outcomes (Forbes)
  • When a Health Insurer Also Wants to Be a Hospice Company (NYT)
Regulatory Reconnaissance is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory news stories from around the globe. Each weekday morning, we aim to bring you the latest highlights of new approvals, meetings, legal and political developments, regulations and guidance, and the latest trends with the potential to impact regulatory affairs professionals and the industry in which they work.

Need to contact the editor of Regulatory Reconnaissance? Email us at

A story's inclusion in Regulatory Reconnaissance does not imply endorsement by Regulatory Focus or RAPS.

Categories: Recon

Regulatory Focus newsletters

All the biggest regulatory news and happenings.